Loading...
•
Mar 31, 2021
Generation Bio Q1 2021 Earnings Report
Generation Bio reported first quarter 2021 financial results and presented preclinical data at ASGCT.
Key Takeaways
Generation Bio reported a net loss of $25.6 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $451.1 million as of March 31, 2021. They also presented data demonstrating the broad potential of their gene therapy platform.
Demonstrated durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model.
Advanced next-generation rapid enzymatic synthesis of closed-ended DNA to increase manufacturing platform efficiency and scale.
Optimized a potent factor VIII construct by leveraging the increased cargo capacity of closed-ended DNA.
Cash, cash equivalents and marketable securities were $451.1 million as of March 31, 2021.